Clinical Trial Update: A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating tiragolumab with atezolizumab-based PEM/CAR pembrolizumab-based therapy in previously untreated advanced non-squamous non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Pembrolizumab (pembrolizumab)
• Pemetrexed (pemetrexed)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-06-03